LEADER 02069nam  2200529   450 
001 9910820082403321
005 20230803024244.0
010   $a1-78084-234-1
035   $a(CKB)2560000000152110
035   $a(EBL)1179656
035   $a(SSID)ssj0001599984
035   $a(PQKBManifestationID)16306847
035   $a(PQKBTitleCode)TC0001599984
035   $a(PQKBWorkID)14892523
035   $a(PQKB)10903111
035   $a(MiAaPQ)EBC1179656
035   $a(Au-PeEL)EBL1179656
035   $a(OCoLC)877767290
035   $a(EXLCZ)992560000000152110
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aNovel approaches in migraine treatment /$feditor, Hans-Christoph Diener
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$dİ2013
215   $a1 online resource (153 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-236-8 
327   $aTitle page; Copyright page; Contents; Foreword. Novel approaches in migraine treatment; 1. Potential treatment targets and the experience with triptans; 2. Calcitonin gene-related peptide receptor antagonists; 3. Lasmiditan; 4. Microglial modulation in migraine; 5. Transcranial magnetic stimulation for migraine treatment; 6. Patent foramen ovale closure; 7. Biofeedback enhances the migraine threshold; 8. Botulinum toxin for migraine treatment; 9. Sphenopalatine ganglion stimulation in primary headaches; 10. Nutraceuticals in migraine treatment; Index
330   $aNovel Approaches in Migraine Treatment
606   $aMigraine$xTreatment
606   $aMigraine$xPrevention
615  0$aMigraine$xTreatment.
615  0$aMigraine$xPrevention.
676   $a616.84912
702   $aDiener$b Hans-Christoph
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910820082403321
996   $aNovel approaches in migraine treatment$94017196
997   $aUNINA